AERI earnings call for the period ending June 30, 2020.
News & Analysis: Aerie Pharmaceuticals
Wall Street has given the eye-care specialist the cold shoulder in 2020. Is that an opportunity for individual investors?
AERI earnings call for the period ending March 31, 2020.
Success in clinical trials doesn't guarantee success on the market.
AERI earnings call for the period ending December 31, 2019.
The eye-care company reported better-than-expected fourth-quarter 2019 product revenue.
Disappointing early sales results for its newest treatments, Rhopressa and Rocklatan, haven't shaken the company's confidence. Wall Street is a different story.
Slow sales of its glaucoma drugs is forcing management to cut its sales guidance.
AERI earnings call for the period ending September 30, 2019.
The small-cap company's shares have fallen 64% in the last year, but a promising drug portfolio might signal an opportunity for investors with a long-term mindset.